CRBU Stock — Caribou Biosciences, Inc.

Up next

Next earnings call

Oct 4, 2027 Est · unconfirmed · in 62 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 20.7 · elevated Equity put/call 0.61

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −22%

below

Price vs 50-day avg −20%

below

RSI (14) 30

neutral

MACD trend Negative

52-week position 5%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −11%

trailing

6-month return +2%

trailing

YTD return −6%

this year

Relative strength −5%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $2 › 200d $2 — 200d above 50d

Institutional flow Distributing

22 of 137 funds reported for Jun 30 · net -66.2K sh shares · +5 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

11.69% of float · ▲ +20.4% MoM · 4.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

137 holders — mid 3-yr range

Squeeze score 67

elevated · 0–100

Fundamentals

Strong

Revenue growth +12%

Y/Y

EPS growth +4%

Y/Y

Free cash flow $-112.4M

Balance sheet $12.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 76%

annualized · 1-yr

Max drawdown −51%

past year

ATR 7.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−22% Bearish

Price vs 50-day avg

−20% Bearish

RSI (14)

30 Neutral

MACD trend

Negative Bearish

52-week position

5% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $2 › 200d $2 — 200d above 50d

Institutional flow Distributing

22 of 137 funds reported for Jun 30 · net -66.2K sh shares · +5 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

11.69% of float · ▲ +20.4% MoM · 4.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

137 holders — mid 3-yr range

Price context

position in its 52-week range

52-wk low $1 Now $1 · 5% 52-wk high $4

vs 200-day avg -22% vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Cash, cash equivalents, and marketable securities	$142.8M	as of December 31, 2025	—
Non-GAAP net loss non-GAAP	$126.8M	full year 2025	—
Non-GAAP net loss per share non-GAAP	$1.36	full year 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CRBU Caribou Biosciences, Inc. this stock	$147.78M	-6.3%	+11.7%	—	11.7%
ONC BeOne Medicines Ltd.	$472.90B	+8.8%	+22179.2%	962.4	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$124.46B	+8.2%	+46.2%	29.1	2.0%
REGN Regeneron Pharmaceuticals, Inc.	$72.88B	-9.8%	+20.8%	17.0	3.3%
ARGX Argenx SE	$54.57B	+4.9%	—	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

140

% held: 38.5%
Reported: 22 of 137
Top holder: Pfizer Inc

Held Float

View

Held by Funds

Fund positions

48

View

Short & Settlement

Short Interest Rising

Shares short

11.6M

Days to cover: 4.9d
Change: +2.0M sh

View

Short Volume

Short vol %

66%

As of: Jul 29, 2026

Short Total

View

Fails to Deliver

FTD shares

70.3K

Value: $118.2K
As of: Jun 29, 2026

View

Off-Exchange

Off-exchange %

58.0%

Week of: May 4, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$11.2M

Net income (FY): $-148.1M
EPS diluted: $-1.59

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 9

View

Proposed Sales

Value

$13.6K

Shares: 6.9K
Filed: Feb 25, 2026

View

Exempt Offerings

Offering

$115.0M

Filed: Mar 5, 2021

View

Earnings & Events

Earnings Calls

Last call

Jun 4, 2026

View

	5D	20D	120D	MTD	YTD
CRBU	-8.0%	-11.3%	+2.1%	-15.3%	-6.3%
SPY	-1.0%	0.0%	+7.4%	-0.8%	+8.6%
vs SPY	-7.0%	-11.3%	-5.4%	-14.6%	-14.9%

CRBU · Caribou Biosciences, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance